Natco Pharma announced the launch of first generic version of Pomalyst? (Pomalidomide) Capsules in 1,2,3,4 mg strengths in the Australian market. The product was launched by NATCOs commercial partner Juno Pharmaceuticals. Pomalidomide is prescribed for treatment of Multiple Myeloma and Kaposi Sarcoma. Pomalyst? registered sales of USD 35.6 million in the Australian market for the year ending 31 March 2022 as per industry sales data.Powered by Capital Market – Live News
Related Tags
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
